- Home
- PDSB
as 11-15-2024 4:00pm EST
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 114.9M | IPO Year: | N/A |
| Target Price: | $15.00 | AVG Volume (30 days): | 526.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.16 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.53 - $6.74 | Next Earning Date: | 11-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest PDS Biotechnology Corporation News
PDSB Breaking Stock News: Dive into PDSB Ticker-Specific Updates for Smart Investing
GuruFocus.com
3 days ago
PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...
Associated Press Finance
4 days ago
PDS Biotechnology: Q3 Earnings Snapshot
GlobeNewswire
4 days ago
PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results
GlobeNewswire
12 days ago
PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time
Zacks
a month ago
PDS Biotechnology (PDSB) Upgraded to Strong Buy: Here's What You Should Know
GlobeNewswire
a month ago
PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine
Zacks
a month ago
Best Momentum Stocks to Buy for October 15th
GlobeNewswire
2 months ago
PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation
Compare PDSB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PDSB PDS Biotechnology Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.